New Data Demonstrates Increasing Prevalence of Essential Tremor (ET) and High Rates of Depression and Anxiety in Patients With ET

BURLINGAME, Calif.–(BUSINESS WIRE)–Cala Health, Inc., a bioelectronic medicine company developing wearable therapies for chronic disease, today reported data demonstrating the increasing prevalence of essential tremor (ET) from 2010 to 2018; a high rate of depression and anxiety in patients with ET; and the safety and efficacy of Cala Trio when used in a real-world setting to treat ET. The data are being reported today in three abstracts at the Virtual ISPOR Europe 2020 conference. ISPOR is the leading professional society for health economics and outcomes research globally.